GlassScriptPhysician profile
Abdelhakim Kasmia
NPI 1821033127
$12,303.06
in general payments reported to CMS, 2019-2025
50 companies · $3,060 in 2025
The $3,060 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $580 · 2021: $189 · 2022: $2,253 · 2023: $3,579 · 2024: $2,119 · 2025: $3,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,029 · Travel and Lodging: $628 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,029.32 |
| Travel and Lodging | $628.45 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,365.57 | 2021-2025 | |
| Lilly USA, LLC | $810.82 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Medtronic, INC. | $754.55 | 2023 | Percept PC Brainsense, Sensight |
| Pfizer INC. | $675.56 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $669.97 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $600.79 | 2019-2024 | Austedo, Ajovy, Austedo Xr |
| Emd Serono, INC. | $576.43 | 2019-2025 | Mavenclad |
| Sk Life Science, INC. | $486.03 | 2022-2025 | |
| Biogen, INC. | $400.37 | 2022-2025 | Vumerity, Tysabri, Leqembi |
| Janssen Biotech, INC. | $375.34 | 2025 | |
| Acadia Pharmaceuticals INC | $363.56 | 2021-2025 | Nuplazid |
| Lundbeck LLC | $352.62 | 2022-2025 | Vyepti, Rexulti |
| Argenx US, INC. | $351.81 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Celgene Corporation | $293.72 | 2022-2025 | Zeposia |
| Genentech USA, INC. | $278.82 | 2019-2024 | Ocrevus, Enspryng |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdelhakim Kasmia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.